溢多利(300381) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥218,937,842.58, representing an increase of 8.97% compared to the same period last year[5] - The net profit attributable to shareholders decreased by 55.08% to ¥4,986,352.56, while the net profit excluding non-recurring gains and losses was ¥2,806,065.20, down 48.09%[5] - Year-to-date revenue reached ¥601,404,536.26, showing a decline of 37.01% compared to the same period last year[5] - Total operating revenue for Q3 2023 was ¥601,404,536.26, a decrease of 37% compared to ¥954,795,050.17 in Q3 2022[18] - The net profit for Q3 2023 was CNY 19,081,380.90, a decrease of 55.7% compared to CNY 43,082,684.51 in the same period last year[19] - The total comprehensive income attributable to the parent company was CNY 11,277,101.84, down from CNY 26,749,522.04 in Q3 2022[19] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥48,535,779.36, down 80.32%[5] - Cash flow from operating activities decreased by 80.32% to CNY 48.54 million, compared to CNY 246.66 million in the previous year, largely due to the sale of the pharmaceutical segment[10] - Cash flow from investing activities decreased by 60.15% to CNY 155.80 million, down from CNY 391.01 million, primarily due to the absence of proceeds from the sale of the pharmaceutical segment's equity[10] - Cash inflow from investment activities was CNY 1,165,662,597.54, slightly lower than CNY 1,168,477,317.30 in the previous year[20] - The net cash flow from financing activities was negative at CNY -211,215,176.43, compared to a positive CNY 29,975,229.93 in Q3 2022[22] Assets and Liabilities - Total assets as of September 30, 2023, were ¥3,019,100,385.84, a decrease of 4.82% from the end of the previous year[5] - Current assets decreased to ¥1,733,966,718.47 as of September 30, 2023, down 15% from ¥2,042,538,530.95 at the beginning of the year[15] - Total liabilities decreased to ¥270,080,739.24, a reduction of 24% from ¥356,262,437.26 at the start of the year[16] - Non-current assets increased to ¥1,285,133,667.37, up 14% from ¥1,129,605,091.67 at the beginning of the year[15] - Cash and cash equivalents decreased to ¥662,031,515.78, down 24% from ¥872,578,744.39 at the start of the year[15] - Inventory decreased to ¥185,172,651.39, a decline of 10% from ¥205,370,123.60 at the beginning of the year[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,657, with no preferred shareholders[12] - The largest shareholder, Zhuhai Jindadi Investment Co., Ltd., holds 30.97% of the shares, amounting to 151,767,378 shares, with 10,152,284 shares pledged[12] - The company has a repurchase account holding 10.88 million shares[12] Operational Metrics - Operating costs decreased by 51.93% to CNY 324.89 million from CNY 675.94 million, reflecting the exclusion of the pharmaceutical segment's costs from the consolidated financial statements[10] - Operating profit for Q3 2023 was ¥36,568,934.67, a decline of 68% from ¥115,919,144.87 in Q3 2022[18] - The company reported a net profit margin of approximately 6.08% for Q3 2023, compared to 12.14% in Q3 2022[18] - The company experienced a significant drop in cash received from sales, totaling CNY 585,450,711.21, down 36.8% from CNY 926,357,329.17 in the same quarter last year[20] - The company incurred a total operating expense of CNY 621,511,791.51, which is a decrease from CNY 869,260,338.18 in Q3 2022[20] Future Outlook - The company plans to focus on new product development and market expansion strategies in the upcoming quarters[17]